This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-27 and is reviewed periodically as new material appears.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
Winter count - Several Native American groups in the Great Plains have used winter counts as pictorial calendars for record-keeping. Writing system – many indigenous American cultures, such as the Olmec, Maya, Aztec, Zapotec, and Toltec, developed Mesoamerican writing systems. Other native peoples to the north—mainly Algonquians—had organized pictographing, a common precursor of writing. (See Massachusett writing systems, Ojibwe writing systems.)
Insulin shock therapy or insulin coma therapy was a form of psychiatric treatment in which patients were repeatedly injected with large doses of insulin in order to produce daily comas over several weeks. It was introduced in 1927 by Austrian-American psychiatrist Manfred Sakel and used extensively in the 1940s and 1950s, mainly for schizophrenia, before falling out of favour and being replaced by neuroleptic drugs in the 1960s. It was one of a number of physical treatments introduced into psychiatry in the first four decades of the 20th century. These included the convulsive therapies (cardiazol/metrazol therapy and electroconvulsive therapy), deep sleep therapy, and psychosurgery. Insulin coma therapy and the convulsive therapies are collectively known as the shock therapies.
Peppermint was first identified in Hertfordshire, England, by a Dr. Eales, a discovery which John Ray published 1696 in the second edition of his book Synopsis Methodica Stirpium Britannicarum. He initially gave it the name Mentha spicis brevioribus et habitioribus, foliis Mentha fusca, sapore fervido piperis and later in his 1704 volume Historia Plantarum he called it Mentha palustris or Peper–Mint. The plant was then added to the London Pharmacopoeia under the name Mentha piperitis sapore in 1721. It was given the name Mentha piperita in 1753 by Carl Linnaeus in his Species Plantarum Volume 2. Linnaeus treated peppermint as a species, but it is now agreed to be a hybrid between Mentha aquatica and Mentha spicata, with M. spicata itself also being considered by some authors to be a hybrid between Mentha longifolia and Mentha suaveolens. Peppermint is a herbaceous, rhizomatous, perennial plant that grows to be 30–90 cm (12–35 in) tall, with smooth stems, square in cross section. The rhizomes are wide-spreading and fleshy, and bear fibrous roots. The leaves can be 4–9 cm (1.6–3.5 in) long and 1.5–4 cm (0.59–1.57 in) broad. They are dark green with reddish veins, with an acute apex and coarsely toothed margins. The leaves and stems are usually slightly fuzzy. The flowers are purple, 6–8 mm (0.24–0.31 in) long, with a four-lobed corolla about 5 mm (0.20 in) diameter; they are produced in whorls (verticillasters) around the stem, forming thick, blunt spikes. Flowering season lasts from mid- to late summer.
In his classic description of diabetes, Aretaeus of Cappadocia (fl. early 2nd century AD) noted the excessive amount of urine that passed through the kidney. He also noted its rarity ("Diabetes is a wonderful affection, not very frequent among men..."). He described the disease as "a melting down of the flesh and limbs into urine" and attributed it to the bladder and kidneys, commenting that "life (with diabetes) is short, disgusting and painful." Aretaeus's contemporary Galen (129–200 AD) stressed that diabetes was a disease of the kidneys and affirmed its rarity, having observed it "only twice" at the time he wrote On the affected parts. Aretaeus and the others authors under discussion did not differentiate between diabetes mellitus and diabetes insipidus. It is assumed that they were referring to diabetes mellitus, although Swedish physician F. Henschen has suggested that Aretaeus and Galen may have instead been referring to diabetes insipidus. For all practical purposes, however, diabetes insipidus remained unrecognized well into the 17th century.
Sources: en.wikipedia.org
Among the 16 genes, the analysis identified two for which rare mutations are known to cause monogenic obesity: MC4R and PCSK1 (proprotein convertase subtilisin/kexin type 1). One study provides genetic evidence linking rare coding variation to BMI and obesity-related phenotypes. MC4R gene mutations are associated with early-onset severe obesity. The effect of two exemplary heterozygous coding variants in the MC4R gene (C293R and S94N) are: • Rapid weight gains from early age (the most important feature). • Development of severe obesity (BMI ≫97th percentile) at early ages, usually <3 years of age. • Persistent food-seeking behavior, mostly reported from six months of age. • Parental/siblings anthropometric data: suspect if relatives present normal anthropometric data. • Tall stature/increased growth velocity (MC4R monogenic diabetes). There is limited treatment options for the most common form of monogenic obesity, MC4R mutations symptoms can be treated with a Glucagon-like Peptide-1 Receptor Agonist liraglutide which cause weight loss by reducing appetite. They found that the effects of liraglutide 3.0 mg daily for 16 weeks causes weight reducing and glucose lowering and may be relevant treatment in the most common form of monogenic obesity.
The four substrates of this enzyme are taxifolin, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are dihydrogossypetin, oxidised NAD+, and water. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. The enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is phenol,NADPH:oxygen oxidoreductase (2-hydroxylating). Other names in common use include phenol hydroxylase, and phenol o-hydroxylase. It uses flavin adenine dinucleotide as a second cofactor. The systematic name of this enzyme class is taxifolin,NAD(P)H:oxygen oxidoreductase (8-hydroxylating). This enzyme is also called taxifolin hydroxylase.
When initially discovered, some scientists proposed that Osedax was a whale-bone specialist, a notion later disproven by the discovery of Osedax on a variety of skeletal substrates including bone fragments, teleost bones, shark teeth, reptile and bird skeletons, pinniped bones, experimentally placed cow bones, and even human remains. Multiple species of Osedax can co-exist in close proximity, even on the same bone. Osedax and their borings enhance local biodiversity by dissolving the tough external cortical bone and tunneling through their internal layers, increasing structural complexity and providing new regions for microfauna to colonize. As such, Osedax are considered ecosystem engineers. However, these borings compromise the structural integrity of the bones, causing them to collapse after extensive boring, rendering these new habitats temporary. The role of Osedax in the degradation of marine vertebrate remains is important to marine vertebrate taphonomy.
Shakey's Pizza is a pizza restaurant chain based in the United States and the Philippines. Founded in 1954, it was the first franchise pizza chain in the United States. In 1968, the chain had 342 locations. As of April 2026, the chain had about 500 stores globally and 43 in the United States. Currently, the stores can be found in the states of California and Washington, as well as in the Philippines, Singapore and Japan.
==== Omega-6:omega-3 ratio ==== A 2024 review stated that dietary recommendations should not be made based on the omega-6:omega-3 ratio, but rather on their absolute dietary intake levels. The omega-6:omega-3 ratio is calculated by accounting for all of the omega-6 fatty acids in the diet or blood divided by the sum of all omega-3 fatty acids. Concern about a high omega-6:omega-3 ratio was based on the competition between linoleic acid and alpha-linolenic acid for desaturation enzymes, and because metabolites of omega-6 fatty acids were considered to be pro-inflammatory. However, there is insufficient evidence in humans that omega-6 fats are pro-inflammatory and that omega-3 fats are anti-inflammatory. In contrast, higher omega-6 levels are associated with lower inflammatory status, indicating that intake of omega-6 fats is not a dietary concern, and that relatively low intake of dietary omega-3 fats may lead to inflammation. Accordingly, use of the omega-6:omega-3 ratio has been rejected as an inflammation biomarker by health agencies worldwide. Numerous health and scientific organizations recommend intake of omega-6 seed oils as part of a healthy diet to replace sources of saturated fats, such as in palm and coconut oils, butter, tallow, and lard.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.